Literature DB >> 21855969

Responsiveness and minimal clinically important change in overactive bladder symptom score.

Momokazu Gotoh1, Yukio Homma, Osamu Yokoyama, Osamu Nishizawa.   

Abstract

OBJECTIVE: To assess the responsiveness and minimal clinically important change (MCIC) in the Overactive Bladder Symptom Score (OABSS), a single score used to quantify overactive bladder symptoms.
METHODS: The data were derived from a clinical trial of propiverine in patients with overactive bladder. The analysis included participants who completed the OABSS, a bladder diary, and patient-reported outcome measures (urgency and incontinence impact) at baseline and 12 weeks. Responsiveness was assessed with effect sizes, correlations between the OABSS items and bladder diary variables, and comparisons between the score changes and symptom improvement. The MCIC was comprehensively estimated from the discriminating thresholds for minimal symptom improvement, and the receiver operating characteristics curve analyses were used to derive cutoff scores for symptom improvement.
RESULTS: A total of 282 participants were included in the present analysis. The effect sizes for the OABSS ranged from -0.369 to -1.485, and correlations between the changes in the OABSS items and the corresponding bladder diary variables were moderate to large. A linear tendency was found between the changes in the OABSS and symptom improvement. The mean change for urgency and incontinence impact was -2.59 and -2.49 for "no change" and -3.67 and -3.78 for "minor improvement," respectively. The optimal cutoff score ranged from -4 to -3. Integrating the MCIC analyses, -3 was estimated as the minimal threshold for a meaningful change.
CONCLUSION: With good responsiveness, the OABSS is a useful tool for assessing the treatment of OAB symptoms. Furthermore, the results of our study suggest that the MCIC of the OABSS is -3.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21855969     DOI: 10.1016/j.urology.2011.06.020

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  17 in total

1.  Reproducibility study of Overactive Bladder Symptom Score questionnaire and its response to treatment (RESORT) in Korean population with overactive bladder symptoms.

Authors:  Seong Jin Jeong; Yukio Homma; Seung-June Oh
Journal:  Qual Life Res       Date:  2013-05-29       Impact factor: 4.147

2.  Psychometric Properties of the Korean Version of the Overactive Bladder Questionnaire (OAB-q) in a Korean Population.

Authors:  Seung-June Oh; Hwancheol Son; Soo Wong Kim; Kyu-Sung Lee; Myung-Soo Choo; Seon-Ok Kim; Moo Song Lee
Journal:  Int Neurourol J       Date:  2012-06-30       Impact factor: 2.835

3.  Duration of Antimuscarinic Administration for Treatment of Overactive Bladder Before Which One Can Assess Efficacy: An Analysis of Predictive Factors.

Authors:  Sheng-Mou Hsiao; Chun-Hou Liao; Ho-Hsiung Lin; Hann-Chorng Kuo
Journal:  Int Neurourol J       Date:  2015-09-22       Impact factor: 2.835

4.  Correlation between overactive bladder symptom score and neuropsychological parameters in Alzheimer's disease patients with lower urinary tract symptom.

Authors:  Ha Bum Jung; Don Kyoung Choi; Seong Ho Lee; Sung Tae Cho; Hae Ri Na; Moon Ho Park
Journal:  Int Braz J Urol       Date:  2017 Mar-Apr       Impact factor: 1.541

5.  Updating the evidence on drugs to treat overactive bladder: a systematic review.

Authors:  Frances C Hsu; Chandler E Weeks; Shelley S Selph; Ian Blazina; Rebecca S Holmes; Marian S McDonagh
Journal:  Int Urogynecol J       Date:  2019-07-25       Impact factor: 2.894

6.  Low Intensity Extracorporeal Shock Wave Therapy as a Potential Treatment for Overactive Bladder Syndrome.

Authors:  Jian-He Lu; Kuang-Shun Chueh; Shu-Mien Chuang; Yi-Hsuan Wu; Kun-Ling Lin; Cheng-Yu Long; Yung-Chin Lee; Mei-Chen Shen; Ting-Wei Sun; Yung-Shun Juan
Journal:  Biology (Basel)       Date:  2021-06-16

7.  Overactive bladder symptom severity is associated with falls in community-dwelling adults: LOHAS study.

Authors:  Noriaki Kurita; Shin Yamazaki; Norio Fukumori; Kenichi Otoshi; Koji Otani; Miho Sekiguchi; Yoshihiro Onishi; Misa Takegami; Rei Ono; Shigeo Horie; Shin-Ichi Konno; Shin-Ichi Kikuchi; Shunichi Fukuhara
Journal:  BMJ Open       Date:  2013-05-03       Impact factor: 2.692

8.  Ramelteon combined with an α1-blocker decreases nocturia in men with benign prostatic hyperplasia.

Authors:  Takashi Kawahara; Satoshi Morita; Hiroki Ito; Hideyuki Terao; Ryoko Sakata; Hitoshi Ishiguro; Katsuyuki Tanaka; Hiroshi Miyamoto; Junichi Matsuzaki; Yoshinobu Kubota; Hiroji Uemura
Journal:  BMC Urol       Date:  2013-06-12       Impact factor: 2.264

9.  Nation-wide epidemiological study of Japanese patients with rare viral myelopathy using novel registration system (HAM-net).

Authors:  Ariella L G Coler-Reilly; Naoko Yagishita; Hiroko Suzuki; Tomoo Sato; Natsumi Araya; Eisuke Inoue; Ayako Takata; Yoshihisa Yamano
Journal:  Orphanet J Rare Dis       Date:  2016-05-25       Impact factor: 4.123

10.  Cognitive behavioral therapy for overactive bladder in women: study protocol for a randomized controlled trial.

Authors:  Satoshi Funada; Norio Watanabe; Takayuki Goto; Hiromitsu Negoro; Shusuke Akamatsu; Kentaro Ueno; Ryuji Uozumi; Kentaro Ichioka; Takehiko Segawa; Tatsuo Akechi; Toshiaki A Furukawa; Osamu Ogawa
Journal:  BMC Urol       Date:  2020-08-20       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.